bioAffinity Technologies, Inc. — Director's Dealing 2022

Dec 3, 2022

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: bioAffinity Technologies, Inc. (BIAF)
CIK: 0001712762
Period of Report: 2022-08-29

Reporting Person: Anderson Robert A. (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$1.16	2024-04-28	Common Stock (64848)		Direct
Stock Option (right to buy)	$4.20	2025-07-27	Common Stock (3571)		Direct
Stock Option (right to buy)	$7.00	2026-07-25	Common Stock (3571)		Direct
Stock Option (right to buy)	$7.00	2027-04-24	Common Stock (3571)		Direct
Stock Option (right to buy)	$7.70	2028-05-07	Common Stock (7142)		Direct
Stock Option (right to buy)	$7.70	2029-07-29	Common Stock (7142)		Direct
Stock Option (right to buy)	$7.70	2030-07-27	Common Stock (7142)		Direct
Stock Option (right to buy)	$4.20	2031-12-16	Common Stock (7142)		Direct

Footnotes

F1: The number of securities and exercise price reported in this Form 3 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").

F2: Represents a right to purchase 64,848 shares of Common Stock upon exercise of a ten-year option granted to Mr. Anderson under the Issuer's 2014 Equity Incentive Plan (the "EIP") on April 28, 2014. This option vested in 7 monthly installments beginning on May 28, 2014 and is fully vested and exercisable as of the date of this report.

F3: Represents a right to purchase 3,571 shares of Common Stock upon exercise of a ten-year option granted to Mr. Anderson under the EIP on July 27, 2015. This option vested in 12 monthly installments beginning on August 27, 2015 and is fully vested and exercisable as of the date of this report.

F4: Represents a right to purchase 3,571 shares of Common Stock upon exercise of a ten-year option granted to Mr. Anderson under the EIP on July 25, 2016. This option vested in 12 monthly installments beginning on August 25, 2016 and is fully vested and exercisable as of the date of this report.

F5: Represents a right to purchase 3,571 shares of Common Stock upon exercise of a ten-year option granted to Mr. Anderson under the EIP on April 24, 2017. This option vested in 12 monthly installments beginning on May 24, 2017 and is fully vested and exercisable as of the date of this report.

F6: Represents a right to purchase 7,142 shares of Common Stock upon exercise of a ten-year option granted to Mr. Anderson under the EIP on May 7, 2018. This option vested in 12 monthly installments beginning on June 7, 2018 and is fully vested and exercisable as of the date of this report.

F7: Represents a right to purchase 7,142 shares of Common Stock upon exercise of a ten-year option granted to Mr. Anderson under the EIP on July 29, 2019. This option vested in 12 monthly installments beginning on August 29, 2019 and is fully vested and exercisable as of the date of this report.

F8: Represents a right to purchase 7,142 shares of Common Stock upon exercise of a ten-year option granted to Mr. Anderson under the EIP on July 27, 2020. This option vested in 12 monthly installments beginning on August 27, 2020 and is fully vested and exercisable as of the date of this report.

F9: Represents a right to purchase 7,142 shares of Common Stock upon exercise of a ten-year option granted to Mr. Anderson under the EIP on December 16, 2021. On January 16, 2022, this option began vesting in 12 monthly installments, the first 11 of which are of 595 shares of Common Stock and the last of which is of the remaining 597 shares of Common Stock, subject to Mr. Anderson's continuous service to the Issuer through each vesting date. As of the date of this report, 4,760 shares of Common Stock underlying this option have vested. The remaining unvested shares of Common Stock will vest immediately prior to the closing of the IPO on September 6, 2022.